Show simple item record

Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial

dc.contributor.authorArmstrong, A. J.
dc.contributor.authorClarke, Noel W
dc.contributor.authorThiery-Vuillemin, A.
dc.contributor.authorOya, M.
dc.contributor.authorProcopio, G.
dc.contributor.authorDe Menezes, J. J.
dc.contributor.authorGirotto, G. C.
dc.contributor.authorGhatalia, P.
dc.contributor.authorDin, F. N. O.
dc.contributor.authorSpiegelhalder, P.
dc.contributor.authorMincik, I.
dc.contributor.authorVan Alphen, R. J.
dc.contributor.authorLumen, N.
dc.contributor.authorHosius, C.
dc.contributor.authorZhou, D. S.
dc.contributor.authorBarker, L.
dc.contributor.authorDujka, M. E.
dc.contributor.authorSaad, F.
dc.date.accessioned2022-11-30T10:21:26Z
dc.date.available2022-11-30T10:21:26Z
dc.date.issued2022en
dc.identifier.citationArmstrong AJ, Clarke NW, Thiery-Vuillemin A, Oya M, Procopio G, De Menezes JJ, et al. Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301470.en
dc.identifier.doi10.1200/JCO.2022.40.16_suppl.5050en
dc.identifier.urihttp://hdl.handle.net/10541/625805
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.16_suppl.5050en
dc.titleOlaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDuke University Medical Center, Durham, NCen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record